CivicaScript,® a nonprofit company dedicated to bringing low-cost generic medicines to U.S. consumers, announced today that it has lowered the price of its lead product, Abiraterone Acetate ...

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction in ...

CivicaScript's first product is hitting the market. | The public benefits company and sister to Civica Rx is making its first generic available: 250mg abiraterone acetate tablets.

CHICAGO — Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic castration-sensitive prostate cancer with homologous recombination ...

Because abiraterone is a generic drug which has gone "off patent" and is licensed for only one group of prostate cancer patients, there is a complicated process to get it approved for wider use.

Janssen submits New Drug Application to the US Food and Drug Administration seeking approval of niraparib and abiraterone acetate dual-action tablet, plus prednisone, as a first-line targeted ...

He was diagnosed with prostate cancer earlier that year but was told that abiraterone could not be obtained on the NHS in England. He chose to pay for treatment with the drug at £250 a month.

AKEEGA TM (niraparib and abiraterone acetate) is an orally administered, tablets of niraparib, a highly selective poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, and abiraterone ...

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer (mHSPC) is associated with a lower risk for progression to castration-resistance.

This orally administered, dual-action tablet (DAT) consists of a combination of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 ...

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction in ...